Objective: This is a retrospective study of 18 patients harboring a solitary fibrous tumor of the central nervous system. Therapeutic management and outcome were analyzed.

Methods: Between 1999 and 2004, 18 patients harboring central nervous system solitary fibrous tumors were surgically treated at our two institutions. There were nine men and nine women. The patient ages ranged from 33 to 75 years, with a median age of 56.1 years. The locations were spinal in six cases (33.3%), the posterior fossa in six cases (33.3%), supratentorial in four cases (22.2%), and orbital in two cases (11.2%).

Results: The median follow-up period was 45.3 months. Gross total resection was achieved in 10 cases (55.6%); tumor recurrence or progression occurred in nine cases (50%). Incomplete surgical resection was significantly associated with recurrence (P = 0.018). On univariate analysis, extent of surgery was also associated with a longer progression-free survival (P = 0.05). No statistically significant correlation can be found between histological features and recurrence.

Conclusion: Prognosis of solitary fibrous tumors of the central nervous system remains unclear; consequently, careful and close monitoring of patients and long-term follow-up are mandatory. Radical surgical excision seems to be a significant and reliable prognosis factor, although pathological prognostic features must be defined. In other respects, the role of postoperative radiotherapy in atypical or incompletely resected solitary fibrous tumors of the central nervous system remains to be determined and, therefore, warrants larger series with longer follow-up periods.

Download full-text PDF

Source
http://dx.doi.org/10.1227/01.NEU.0000255418.93678.ADDOI Listing

Publication Analysis

Top Keywords

solitary fibrous
20
central nervous
20
nervous system
20
fibrous tumors
16
tumors central
12
patients harboring
8
cases 333%
8
system remains
8
cases
7
solitary
5

Similar Publications

To investigate the clinicopathological and molecular genetic characteristics of intracranial mesenchymal tumors with FET::CREB fusion transcript. The clinical and imaging data of 6 cases of intracranial mesenchymal tumors with FET::CREB fusion from December 2018 to December 2023 were collected at the First Affiliated Hospital of Zhengzhou University. Their histological features, immunophenotype and molecular characteristics were analyzed.

View Article and Find Full Text PDF

Cinematic rendering of pleural solitary fibrous tumor.

Radiol Case Rep

March 2025

Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 601 N Caroline St, Baltimore, MD, 21287, USA.

Solitary fibrous tumors are rare and typically benign fibroblastic neoplasms with a mean age of onset ranging from 60 to 70 years. Solitary fibrous tumors may arise anywhere within the body, however the pleura is the most common site of origin for these tumors, with approximately 30% of tumors arising from the pleura. In this report we highlight the case of a 62-year-old woman who presented with gradually progressive left sided chest pain that was eventually diagnosed as a pleural SFT.

View Article and Find Full Text PDF

Solitary fibrous tumours (SFTs) are rare soft tissue masses that are often clinically silent until they cause mass effect. A paraneoplastic syndrome manifesting as persistent hypoglycaemia, termed Doege-Potter syndrome (DPS), can be associated with these lesions. Surgical treatment is recommended for the management of these tumours.

View Article and Find Full Text PDF

Introduction: Solitary fibrous bladder tumors are extremely uncommon, with only a few cases reported. These fibroblastic mesenchymal neoplasms are typically benign, indolent, and slow growing.

Case Presentation: A 44-year-old male patient with obstructive uropathy was referred to our unit for workup.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!